RCS - Immupharma PLC - IMMUPHARMA AT BIO-EUROPE SPRING 2024

ImmuPharmaAnnouncement

14/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN7721Ga&default-theme=true

RNS Number : 7721G  Immupharma PLC  14 March 2024

RNS REACH |14 March 2024

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA AT BIO-EUROPE SPRING 2024

18-20 March 2024 | Barcelona

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be
attending BIO-Europe Spring. The event will be held between 18-20 March 2024,
in Barcelona.

 

BIO-Europe Spring is the premier springtime partnering event, designed to
provide biotechnology companies with the opportunity to present to and connect
with investors together with the global biopharma community.

 

Commenting on the event, Tim McCarthy, CEO of ImmuPharma said: "Following on
from our recent announcements, including moving our lead asset P140 for SLE
(Lupuzor™) forward, with our appointed CRO, Simbec-Orion, in parallel with
our CIDP program, we are delighted to have BIO-Europe as the next key platform
in 2024 to present our unique portfolio to key industry and investment
specialists. Our focus will be to secure partnering opportunities across our
programs including our P140 platform and our earlier stage but highly exciting
anti-infective asset, BioAMB."

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer                                 + 44 (0) 7721 413496

 Lisa Baderoon, Head of Investor Relations

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140/SLE (Lupuzor™), P140 "restores" the
immune system back to normal, by enabling tolerogenic antigen presenting cells
to function properly. P140 is not an immunosuppressant unlike other molecules
in development. P140 is extremely safe, well-tolerated and patient friendly,
and potentially can be self-administered through a subcutaneous injection,
once a month for SLE.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About BIO-Europe Spring, Barcelona, 2024

 

Connecting the global biopharma community to elevate life science
partnerships.

 

BIO-Europe Spring, is the premier springtime partnering event, bringing
together over 3,700 attendees from 2,000+ companies to engage in 20,000
one-to-one meetings.

 

For more information go to: https://informaconnect.com/bioeurope-spring/
(https://informaconnect.com/bioeurope-spring/)

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAJJMPTMTBBBPI